Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
OKL-1111 by Alveron Pharma for Brain Hemorrhage: Likelihood of Approval
OKL-1111 is under clinical development by Alveron Pharma and currently in Phase I for Brain Hemorrhage. According to GlobalData, Phase...